Clemons M - Search Results

1

Radiological changes following second-line zoledronic acid treatment in breast cancer patients with bone metastases.

Amir E, Whyne C, Freedman OC, Fralick M, Kumar R, Hardisty M, Clemons M. Amir E, et al. Among authors: clemons m. Clin Exp Metastasis. 2009;26(5):479-84. doi: 10.1007/s10585-009-9247-x. Epub 2009 Mar 6. Clin Exp Metastasis. 2009. PMID: 19266291

2

Estrogen and the risk of breast cancer.

Clemons M, Goss P. Clemons M, et al. N Engl J Med. 2001 Jan 25;344(4):276-85. doi: 10.1056/NEJM200101253440407. N Engl J Med. 2001. PMID: 11172156 Review. No abstract available.

3

Utilization of palliative radiotherapy for breast cancer patients with bone metastases treated with bisphosphonates-Toronto Sunnybrook Regional Cancer Centre experience.

Enright K, Clemons M, Chow E. Enright K, et al. Among authors: clemons m. Support Care Cancer. 2004 Jan;12(1):48-52. doi: 10.1007/s00520-003-0548-3. Epub 2003 Oct 24. Support Care Cancer. 2004. PMID: 14577020

4

Should all breast cancer patients with symptomatic bone metastases be treated with bisphosphonates? The case in support.

Clemons M. Clemons M. Clin Oncol (R Coll Radiol). 2004 Apr;16(2):108-11. doi: 10.1016/j.clon.2004.01.004. Clin Oncol (R Coll Radiol). 2004. PMID: 15074732 No abstract available.

5

Treatment of locally advanced breast cancer.

Verma S, Clemons M, Fitzgerald B, Freedman O. Verma S, et al. Among authors: clemons m. CMAJ. 2004 Aug 3;171(3):219; author reply 221-2. doi: 10.1503/cmaj.1040532. CMAJ. 2004. PMID: 15289404 Free PMC article. No abstract available.

6

Bisphosphonate use for the management of breast cancer patients with bone metastases: a survey of Canadian Medical Oncologists.

Verma S, Kerr-Cresswell D, Dranitsaris G, Charbonneau F, Trudeau M, Yogendran G, Cesta AM, Clemons M. Verma S, et al. Among authors: clemons m. Support Care Cancer. 2004 Dec;12(12):852-8. doi: 10.1007/s00520-004-0671-9. Epub 2004 Aug 21. Support Care Cancer. 2004. PMID: 15322969

7

Perspectives on the future of bisphosphonate use in breast cancer patients.

Clemons M, Rea D. Clemons M, et al. Semin Oncol. 2004 Oct;31(5 Suppl 10):87-91. doi: 10.1053/j.seminoncol.2004.07.029. Semin Oncol. 2004. PMID: 15490383 Review.

8

Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?

Freedman OC, Verma S, Clemons MJ. Freedman OC, et al. Among authors: clemons mj. Cancer Treat Rev. 2005 Feb;31(1):1-17. doi: 10.1016/j.ctrv.2004.09.008. Epub 2004 Nov 18. Cancer Treat Rev. 2005. PMID: 15707700 Review.

9

Can bone markers guide more effective treatment of bone metastases from breast cancer?

Clemons M, Cole DE, Gainford MC. Clemons M, et al. Breast Cancer Res Treat. 2006 May;97(1):81-90. doi: 10.1007/s10549-005-9094-7. Epub 2005 Dec 1. Breast Cancer Res Treat. 2006. PMID: 16319976 Review.

10

Too much, too little, too late to start again? Assessing the efficacy of bisphosphonates in patients with bone metastases from breast cancer.

Clemons M, Dranitsaris G, Cole D, Gainford MC. Clemons M, et al. Oncologist. 2006 Mar;11(3):227-33. doi: 10.1634/theoncologist.11-3-227. Oncologist. 2006. PMID: 16549806 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

409 results

Search Page

Filters